Level 1 evidence, presented at EUROSPINE 2018 in Barcelona, Spain, demonstrates that i-FACTOR peptide enhanced bone graft results in significantly higher rates of fusion in uninstrumented lumbar spinal surgery than does the use of allograft.
Michael Jacobsen (Middelfart, Denmark) spoke to Spinal News International at the conference about the findings from the trial and their implications.
In the single centre, double-blind, randomised IVANOS study, 98 patients (240 treated levels) aged 60 and older with lumbar spinal stenosis and concomitant degenerative olisthesis were treated with non-instrumented lumbar posterolateral spine surgery and received either i-FACTOR peptide enhanced bone graft or allograft. Results demonstrated a 50% fusion rate using i-FACTOR compared to a 20% fusion rate using allograft at one-year postoperative follow-up. Patients with one-level degenerative olisthesis achieved estimated fusion rates of 40% with i-FACTOR peptide enhanced bone graft vs. 21% with allograft. Patients with two-level degenerative olisthesis achieved estimated fusion rates of 63% with i-FACTOR vs. 18% with allograft.[/vc_column_text][/vc_column][/vc_row]